ESCR
MCID: ESP021
MIFTS: 83

Esophageal Cancer (ESCR)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Esophageal Cancer

MalaCards integrated aliases for Esophageal Cancer:

Name: Esophageal Cancer 57 38 12 53 75 37 13 43 15
Esophageal Squamous Cell Carcinoma 57 59 75 6
Esophageal Carcinoma 12 55 15 73
Carcinoma of Esophagus 12 29 6
Esophageal Squamous Cell Carcinoma, Somatic 57 6
Esophageal Carcinoma, Somatic 57 6
Gastric Cardia Adenocarcinoma 75 73
Esophageal Neoplasms 44 73
Esophagus Cancer 12 53
Escc 59 75
Malignant Tumor of the Middle Third of the Esophagus 12
Malignant Neoplasm of Proximal Third of Esophagus 12
Malignant Neoplasm of Middle Third of Oesophagus 12
Malignant Neoplasm of Distal Third of Esophagus 12
Malignant Neoplasm of Lower Third of Oesophagus 12
Malignant Neoplasm of Middle Third of Esophagus 73
Malignant Tumor of Proximal Third of Esophagus 12
Malignant Tumor of Distal Third of Esophagus 12
Malignant Neoplasm of Upper Third Esophagus 12
Squamous Cell Carcinoma of the Esophagus 59
Malignant Tumor of Abdominal Esophagus 12
Squamous Cell Carcinoma of Esophagus 73
Esophageal Epidermoid Carcinoma 59
Squamous Cell Esophageal Cancer 55
Malignant Neoplasm of Esophagus 73
Esophageal Cancer, Somatic 57
Ca Middle Third Oesophagus 12
Aerodigestive Tract Cancer 75
Ca Lower Third Oesophagus 12
Carcinoma of Oesophagus 12
Cancer of Oesophagus 12
Cancer of Esophagus 12
Esophageal Neoplasm 76
Cancer, Esophageal 40
Escr 75

Characteristics:

Orphanet epidemiological data:

59
squamous cell carcinoma of the esophagus
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Adult; Age of death: adult;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
esophageal cancer:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Esophageal Cancer

NIH Rare Diseases : 53 Esophageal cancer is a cancer of the esophagus, the hollow tube that carries foods and liquids from the throat to the stomach. Symptoms that may develop as the cancer grows include heartburn, pain when swallowing, difficulty swallowing, a hoarse voice, a cough that does not go away, weight loss, and coughing up blood. The exact cause of esophageal cancer usually is not known, but both environmental and genetic factors are thought to play a role in its development. For example, variations or mutations in any of several genes may cause susceptibility to esophageal cancer.Environmental factors that may increase a person's chance to develop esophageal cancer include tobacco use, heavy alcohol use, older age, obesity, and damage to the esophagus from acid reflux (Barrett esophagus). The diagnosis may be based on imaging studies and tests such as chest X-ray, upper endoscopy, and a biopsy of tissue from the esophagus. Treatment options and the chance of recovery depend on the stage of the cancer, whether it can be surgically removed, and a person's general health. Treatment options may include surgery, radiation therapy, chemotherapy, laser therapy, and electrocoagulation. Other treatment options, such as targeted therapy, are being studied in clinical trials. When it is found very early, there is a better chance of recovery. When the cancer is more advanced, it can be treated but rarely can be cured.

MalaCards based summary : Esophageal Cancer, also known as esophageal squamous cell carcinoma, is related to adenocarcinoma and esophageal basaloid squamous cell carcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Esophageal Cancer is WWOX (WW Domain Containing Oxidoreductase), and among its related pathways/superpathways are MicroRNAs in cancer and Activation of cAMP-Dependent PKA. The drugs Actiq and Adcetris have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and testes, and related phenotypes are nausea and vomiting and feeding difficulties in infancy

Disease Ontology : 12 A gastrointestinal system cancer that is located in the esophagus.

OMIM : 57 Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most common cancers worldwide. Both environmental and genetic risk factors play a role in the pathogenesis of the disorder. In Europe and North America, heavy smoking, alcohol consumption, and increased body mass index (BMI) are the main environmental risk factors. In contrast, the particularly high incidence of ESCC in some areas of China, central Asia, and southern Africa is associated with nutritional deficiencies, high intake of nitrosamine-rich or pickled vegetables, and low socioeconomic status; smoking, alcohol consumption, and BMI play a lesser role in these populations. There is a tendency for familial aggregation of ESCC in high-risk geographic areas, suggesting a genetic component to increased susceptibility. Gastric cardia adenocarcinoma is another common type of cancer in China that shows similarities to ESCC in terms of geographic distribution and environmental risk factors (summary by Wang et al., 2010 and Abnet et al., 2010). (133239)

MedlinePlus : 43 The esophagus is a hollow tube that carries food and liquids from your throat to your stomach. Early esophageal cancer usually does not cause symptoms. Later, you may have symptoms such as Painful or difficult swallowing Weight loss A hoarse voice or cough that doesn't go away You're at greater risk for getting esophageal cancer if you smoke, drink heavily, or have acid reflux. Your risk also goes up as you age Your doctor uses imaging tests and a biopsy to diagnose esophageal cancer. Treatments include surgery, radiation, and chemotherapy. You might also need nutritional support, since the cancer or treatment may make it hard to swallow. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 75 Esophageal cancer: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage.

Wikipedia : 76 Esophageal cancer is cancer arising from the esophagus�??the food pipe that runs between the throat and... more...

Related Diseases for Esophageal Cancer

Diseases related to Esophageal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.8 TP53 TGFBR2 SMAD4 PIK3CA KRAS HRAS
2 esophageal basaloid squamous cell carcinoma 32.5 WWOX TP53 EGFR CTNNB1
3 gastric adenocarcinoma 31.5 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
4 squamous cell carcinoma 31.3 WWOX TP53 TGFBR2 SMAD4 RNF6 PIK3CA
5 gastric cancer 31.0 TP53 TGFBR2 SMAD4 PIK3CA MIR34A MIR21
6 in situ carcinoma 31.0 EGFR ERBB2 TP53
7 lung cancer 30.8 TP53 TGFBR2 PIK3CA MIR34A MIR21 MIR148A
8 carcinosarcoma 30.6 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
9 barrett's adenocarcinoma 30.6 ERBB2 KRAS TP53
10 hepatocellular carcinoma 30.6 TP53 TGFBR2 SMAD4 PIK3CA MIR34A MIR30E
11 breast cancer 30.5 WWOX TP53 TGFBR2 SMAD4 PIK3CA MIR373
12 colorectal cancer 30.5 TP53 TGFBR2 SMAD4 PIK3CA MIR34A MIR21
13 esophageal disease 30.5 WWOX TP53 ERBB2 EGFR
14 esophagus adenocarcinoma 30.4 TP53 SMAD4 MIR21 ERBB2
15 adenoid cystic carcinoma 30.4 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
16 bladder cancer 30.4 EGFR ERBB2 HRAS KRAS MIR21 TP53
17 ovarian cancer 30.3 CTNNB1 EGFR ERBB2 KRAS MIR126 MIR21
18 ovarian cancer 1 30.3 TP53 PIK3CA KRAS ERBB2
19 small cell cancer of the lung 30.2 EGFR MIR21 PIK3CA TP53
20 nasopharyngeal carcinoma 30.2 TP53 TGFBR2 PIK3CA HRAS EGFR CTNNB1
21 colorectal adenocarcinoma 30.2 TP53 KRAS HRAS EGFR CTNNB1
22 lung cancer susceptibility 3 30.2 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
23 adenoma 30.2 CTNNB1 KRAS SMAD4 TGFBR2 TP53
24 pancreas adenocarcinoma 30.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
25 prostate cancer 30.2 TP53 PIK3CA MIR34A MIR21 MIR148A MIR126
26 thyroid cancer 30.2 CTNNB1 EGFR HRAS KRAS PIK3CA TP53
27 cervical cancer 30.2 TP53 SMAD4 PIK3CA MIR21 HRAS ERBB2
28 leukemia, chronic lymphocytic 2 30.2 HRAS KRAS MIR34A TP53
29 oral cancer 30.2 EGFR MIR21 TP53
30 squamous cell carcinoma, head and neck 30.1 TP53 SMAD4 PIK3CA MIR373 MIR21 MIR148A
31 familial adenomatous polyposis 30.1 CTNNB1 KRAS SMAD4 TP53
32 kidney cancer 29.8 MIR126 MIR21 TP53
33 tylosis with esophageal cancer 12.7
34 esophageal cancer, childhood 12.1
35 mucoepidermoid esophageal carcinoma 12.1
36 esophagus small cell carcinoma 11.4
37 esophagus squamous cell carcinoma 11.3
38 esophagus verrucous carcinoma 11.1
39 esophageal adenoid cystic carcinoma 11.1
40 esophageal adenosquamous carcinoma 11.1
41 carcinoma of esophagus, salivary gland type 11.0
42 undifferentiated carcinoma of esophagus 11.0
43 palmoplantar keratoderma, epidermolytic 11.0
44 esophagus sarcoma 11.0
45 basaloid squamous cell carcinoma 10.6
46 stomach disease 10.6 WWOX TP53 ERBB2 EGFR CTNNB1
47 adamantinoma of long bones 10.6 TP53 PIK3CA KRAS ERBB2 EGFR CTNNB1
48 endometrial adenocarcinoma 10.5 TP53 KRAS ERBB2 EGFR CTNNB1
49 lynch syndrome 10.5 TP53 TGFBR2 KRAS EGFR CTNNB1
50 glioma 10.5 TP53 PIK3CA MIR34A MIR21 ERBB2 EGFR

Comorbidity relations with Esophageal Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Deficiency Anemia
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Heart Disease
Neutropenia Protein-Energy Malnutrition
Swallowing Disorders

Graphical network of the top 20 diseases related to Esophageal Cancer:



Diseases related to Esophageal Cancer

Symptoms & Phenotypes for Esophageal Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
esophageal cancer

Misc:
frequent loss of heterozygosity of apc and/or mcc genes


Clinical features from OMIM:

133239

Human phenotypes related to Esophageal Cancer:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
2 feeding difficulties in infancy 59 32 hallmark (90%) Very frequent (99-80%) HP:0008872
3 abnormality of the voice 59 32 frequent (33%) Frequent (79-30%) HP:0001608
4 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
5 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
6 lymphadenopathy 59 32 frequent (33%) Occasional (29-5%) HP:0002716
7 clinodactyly of the 5th toe 59 32 hallmark (90%) Very frequent (99-80%) HP:0001864
8 esophageal carcinoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0011459
9 obesity 32 occasional (7.5%) HP:0001513
10 dysphagia 32 hallmark (90%) HP:0002015
11 recurrent singultus 32 frequent (33%) HP:0100247
12 gastroesophageal reflux 32 frequent (33%) HP:0002020
13 weight loss 32 hallmark (90%) HP:0001824
14 abnormality of the neck 32 frequent (33%) HP:0000464
15 squamous cell carcinoma 32 HP:0002860
16 barrett esophagus 32 occasional (7.5%) HP:0100580
17 abnormal intestine morphology 32 occasional (7.5%) HP:0002242

UMLS symptoms related to Esophageal Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, tinnitus, snoring, coughing, sore throat, icterus, vertigo/dizziness, equilibration disorder, dyspepsia, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Esophageal Cancer according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.69 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.69 KRAS
3 Decreased viability GR00107-A-1 10.69 TGFBR2
4 Decreased viability GR00221-A-1 10.69 EGFR HRAS KRAS PIK3CA TGFBR2
5 Decreased viability GR00221-A-2 10.69 HRAS KRAS PIK3CA DCC
6 Decreased viability GR00221-A-3 10.69 HRAS TGFBR2 DCC ERBB2
7 Decreased viability GR00221-A-4 10.69 EGFR PIK3CA TGFBR2 DCC ERBB2
8 Decreased viability GR00301-A 10.69 KRAS
9 Decreased viability GR00381-A-1 10.69 KRAS
10 Decreased viability GR00402-S-2 10.69 EGFR HRAS KRAS PIK3CA TGFBR2 DCC
11 Decreased cell migration GR00055-A-1 9.65 CTNNB1 EGFR HRAS KRAS PIK3CA
12 Increased cell death HMECs cells GR00103-A-0 9.43 CTNNB1 EGFR PIK3CA TGFBR2 TP53 WWOX
13 Increased cell migration GR00055-A-3 9.02 CTNNB1 EGFR HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Esophageal Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 CTNNB1 DCC EGFR ERBB2 KRAS LZTS1
2 endocrine/exocrine gland MP:0005379 10.18 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
3 digestive/alimentary MP:0005381 10.16 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
4 neoplasm MP:0002006 10.15 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
5 craniofacial MP:0005382 10.13 CTNNB1 EGFR ERBB2 HRAS KRAS SMAD4
6 embryo MP:0005380 10.1 CTNNB1 EGFR ERBB2 KRAS PIK3CA SMAD4
7 nervous system MP:0003631 10.1 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
8 integument MP:0010771 10.06 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA
9 muscle MP:0005369 10.01 CTNNB1 EGFR ERBB2 KRAS PIK3CA SMAD4
10 liver/biliary system MP:0005370 9.98 CTNNB1 EGFR KRAS SMAD4 TGFBR2 TP53
11 no phenotypic analysis MP:0003012 9.8 CTNNB1 EGFR HRAS KRAS PIK3CA TP53
12 respiratory system MP:0005388 9.56 CTNNB1 DCC EGFR ERBB2 HRAS KRAS
13 pigmentation MP:0001186 9.55 CTNNB1 DCC EGFR KRAS TP53
14 skeleton MP:0005390 9.32 CTNNB1 EGFR ERBB2 HRAS KRAS PIK3CA

Drugs & Therapeutics for Esophageal Cancer

FDA approved drugs:

(show top 50) (show all 71)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Actiq 18 FENTANYL (citrate) Anesta Corporation November 1998
2
Adcetris 18 49 BRENTUXIMAB VEDOTIN Seattle Genetics August 2011
3
Aromasin Tablets 18 49 EXEMESTANE Pharmacia & Upjohn October 21. 1999
4
Beleodaq 18 49 BELINOSTAT Spectrum Pharmaceuticals July 2014
5
Farydak 18 49 PANOBINOSTAT LACTATE Novartis February 2015
6
Faslodex 18 49 FULVESTRANT AstraZeneca April 2002
7
Gardasil 18 49 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006
8
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
9
Ibrance 18 49 PALBOCICLIB Pfizer February 2015
10
Inlyta 18 49 AXITINIB Pfizer January 2012
11
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
12
Keytruda 18 49 PEMBROLIZUMAB Merck September 2014
13
Lynparza 18 49 OLAPARIB AstraZeneca December 2014
14
Nolvadex 18 49 TAMOXIFEN CITRATE AstraZeneca October 1998
15
Opdivo 18 49 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014, March 2015
16
Photodynamic Therapy (& Photofrin) 18 PORFIMER SODIUM Sanofi-aventis January, 1996
17
Photofrin 18 PORFIMER SODIUM QLT January 1998
18
Zevalin 18 49 IBRITUMOMAB TIUXETAN Biogen IDEC February 2002
19
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
20
Zykadia 18 49 CERITINIB Novartis April 2014
21
Advair 18 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE GlaxoSmithKline August 2000
22
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015
23
Allegra 18 FEXOFENADINE HYDROCHLORIDE Hoechst Marion Roussel July 1996
24
Allegra-D 18 FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE Hoechst Marion Roussel March 1998
25
Augmentin 18 AMOXICILLIN; CLAVULANATE POTASSIUM SmithKline Beecham February 1996
26
Azmacort 18 TRIAMCINOLONE ACETONIDE Rhone Poulenc Rorer November 1996
27
Breathe Right 18 CNS June 1996
28
Cafcit Injection 18 CAFFEINE CITRATE Roxane Laboratories September 1999
29
Cedax 18 CEFTIBUTEN DIHYDRATE Schering-Plough December 1995
30
Cefazolin and Dextrose USP 18 CEFAZOLIN SODIUM B Braun Medical July 2000
31
Claritin RediTabs 18 LORATADINE Schering-Plough January 1997
32
Claritin-D 24 Hour Extended Release Tablets 18 LORATADINE; PSEUDOEPHEDRINE SULFATE Schering-Plough August 1996
33
Covera-HS 18 VERAPAMIL HYDROCHLORIDE GD Searle, Alza January 1996
34
Daliresp 18 ROFLUMILAST Forest Pharmaceuticals February 2011
35
Dulera 18 FORMOTEROL FUMARATE; MOMETASONE FUROATE Merck June 2010
36
DuoNeb 18 ALBUTEROL SULFATE; IPRATROPIUM BROMIDE Dey Laboratories March 2001
37
Esbriet 18 PIRFENIDONE InterMune October 2014
38
Foradil Aerolizer 18 FORMOTEROL FUMARATE Novartis February 2001 (asthma, bronchospasm); September 2001 (COPD)
39
Grastek 18 Timothy Grass Pollen Allergen Extract Merck April 2014
40
Iressa 18 GEFITINIB AstraZeneca May 2003
41
Kalydeco 18 IVACAFTOR Vertex Pharmaceuticals January of 2012
42
Letairis 18 AMBRISENTAN Gilead June 2007
43
Nucala 18 MEPOLIZUMAB GlaxoSmithKline November 2015
44
Orkambi 18 IVACAFTOR; LUMACAFTOR Vertex Pharmaceuticals July 2015
45
Patanase 18 OLOPATADINE HYDROCHLORIDE Alcon April 2008
46
Portazza 18 NECITUMUMAB Eli Lilly November 2015
47
Priftin 18 RIFAPENTINE Hoechst Marion Roussel June 1998
48
Pulmozyme 18 DORNASE ALFA Genentech December 1996|March 1998
49
Qvar 18 BECLOMETHASONE DIPROPIONATE Ivax May 2002
50
Ragwitek 18 Merck April 2014

Drugs for Esophageal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 515)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pravastatin Approved Phase 4 81093-37-0 54687
2
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
3
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
4
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 51-43-4 5816
5
Racepinephrine Approved Phase 4,Phase 2,Not Applicable 329-65-7 838
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
7
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
8
Iron Approved Phase 4,Phase 1 7439-89-6 23925
9
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
10
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
11
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
12
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
14
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
15
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 68538-85-2
16
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
17
Dobutamine Approved Phase 4 34368-04-2 36811
18
Phenylephrine Approved Phase 4 59-42-7 6041
19
Norepinephrine Approved Phase 4 51-41-2 439260
20
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
21
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
27
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
28
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
29
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
30
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7689-03-4
31
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
32 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Lipid Regulating Agents Phase 4,Phase 1
34 Anticholesteremic Agents Phase 4
35 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
36 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Hypolipidemic Agents Phase 4,Phase 1
38 Vitamins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
39 Omega 3 Fatty Acid Phase 4,Phase 2
40 Epinephryl borate Phase 4,Phase 2,Not Applicable
41 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1
44 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
46 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Ferric Compounds Phase 4
48 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Hematinics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Cola Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1413)
# Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
3 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
4 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
5 Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX Unknown status NCT02609425 Phase 4
6 Postoperative Pain Management After Minimally Invasive Esophagectomy Unknown status NCT02042313 Phase 4
7 Radiofrequency in the Treatment of Barrett's Oesophagus Unknown status NCT02558504 Phase 4
8 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
9 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
10 trūFreeze® Palliative Esophageal Cancer Recruiting NCT03243734 Phase 4
11 Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer Completed NCT00911092 Phase 4 Chemotherapy (Fluorouracil and Cisplatin)
12 Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma Not yet recruiting NCT03413436 Phase 4 Lobaplatin;Cisplatin
13 INEC Study: Immuno-modulating Enteral Nutrition in Cancer Completed NCT00333099 Phase 4
14 Decreasing Postoperative Complications by Goal-Directed Fluid Therapy During Esophageal Resection Completed NCT01416077 Phase 4
15 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
16 Study of CryoSpray Ablation(TM)to Determine Treatment Effect, Depth of Injury, and Side Effects in the Esophagus. Completed NCT00754468 Phase 4
17 Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy Completed NCT02320734 Phase 4 Rocuronium
18 HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery Enrolling by invitation NCT03642093 Phase 4
19 The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Not yet recruiting NCT02845479 Phase 4
20 The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery Completed NCT02439905 Phase 4 Dexmedetomidine;Placebo control
21 Barretts oEsophageal Resection With Steroid Therapy Trial Not yet recruiting NCT02004782 Phase 4 Prednisolone;Placebo Oral Tablet
22 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
23 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
24 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
25 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
26 Low-dose Aspirin Therapy for Esophageal Cancer Unknown status NCT02326779 Phase 3 Acetylsalicylic acid
27 Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer Unknown status NCT02355249 Phase 3
28 Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer Unknown status NCT02866019 Phase 3
29 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
30 a Multicentric Randomized Controlled Trial of Self-Expandable Esophageal Radiation Stent Unknown status NCT01054274 Phase 3
31 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
32 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
33 Comparable Study of Different Radiation Dose in Esophageal Carcinoma Unknown status NCT01937208 Phase 3 concurrent chemotherapy with radiation
34 Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer Unknown status NCT00686114 Phase 3 Paclitaxel;Cisplatin;Tarceva
35 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
36 Combination Chemotherapy in Treating Patients With Esophageal Cancer Unknown status NCT00041262 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
37 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
38 Esophagectomy Associated Respiratory Complications: Ivor-Lewis Versus Sweet Approaches Unknown status NCT01053182 Phase 3
39 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
40 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Unknown status NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
41 Impact of the Techniques for Intrathoracic Esophagogastric Anastomosis on Outcome in Ivor-Lewis Oesophagectomy Unknown status NCT01242124 Phase 2, Phase 3
42 Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial Unknown status NCT00193817 Phase 3
43 The Effects of Gastric Tube on the Quality of Life and Nutritional Status After Ivor-Lewis Esophagectomy Unknown status NCT01361750 Phase 3
44 Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial Unknown status NCT02780921 Phase 3
45 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
46 Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers Unknown status NCT01911832 Phase 3
47 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Unknown status NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
48 Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Unknown status NCT02375997 Phase 3
49 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Unknown status NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
50 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel

Search NIH Clinical Center for Esophageal Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Esophageal Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Esophageal Cancer:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Esophageal Cancer:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: esophageal neoplasms

Genetic Tests for Esophageal Cancer

Genetic tests related to Esophageal Cancer:

# Genetic test Affiliating Genes
1 Carcinoma of Esophagus 29

Anatomical Context for Esophageal Cancer

MalaCards organs/tissues related to Esophageal Cancer:

41
Lung, Lymph Node, Testes, T Cells, Skin, Breast, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Esophageal Cancer:

19
The Esophagus

Publications for Esophageal Cancer

Articles related to Esophageal Cancer:

(show top 50) (show all 3994)
# Title Authors Year
1
Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression. ( 30551480 )
2019
2
MicroRNA‑301a targets WNT1 to suppress cell proliferation and migration and enhance radiosensitivity in esophageal cancer cells. ( 30365079 )
2019
3
Diagnosis and survival values of neutrophil-lymphocyte ratio (NLR) and red blood cell distribution width (RDW) in esophageal cancer. ( 30389457 )
2019
4
Knockdown of USP28 enhances the radiosensitivity of esophageal cancer cells via the c-Myc/hypoxia-inducible factor-1 alpha pathway. ( 30206969 )
2019
5
Esophageal cancer lymph node metastasis-associated gene signature optimizes overall survival prediction of esophageal cancer. ( 30242875 )
2019
6
Comparative Study of Predictive Mortality Scores in Esophagectomy with Three-Field Lymph Node Dissection in Patients with Esophageal Cancer. ( 29393197 )
2019
7
Phospho-Sphingosine Kinase 1 Expression in Lymphatic Spread of Esophageal Squamous Cell Carcinoma. ( 30527463 )
2019
8
SRPX2 knockdown inhibits cell proliferation and metastasis and promotes chemosensitivity in esophageal squamous cell carcinoma. ( 30551519 )
2019
9
MicroRNA-384 inhibits the progression of esophageal squamous cell carcinoma through blockade of the LIMK1/cofilin signaling pathway by binding to LIMK1. ( 30551528 )
2019
10
Dysregulated circRNAs and ceRNA network in esophageal squamous cell carcinoma. ( 30468655 )
2019
11
PADI4 stimulates esophageal squamous cell carcinoma tumor growth and up-regulates CA9 expression. ( 30242913 )
2019
12
Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis. ( 30182448 )
2019
13
The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. ( 30070689 )
2019
14
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. ( 29966526 )
2018
15
The Prediction of Deterioration of Nutritional Status during Chemoradiation Therapy in Patients with Esophageal Cancer. ( 29324061 )
2018
16
Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer. ( 29951987 )
2018
17
Pulmonary actinomycosis mimicking a lung metastasis from esophageal cancer; a case report. ( 29486747 )
2018
18
Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. ( 29948480 )
2018
19
Esophageal cancer male to female incidence ratios in Africa: A systematic review and meta-analysis of geographic, time and age trends. ( 29414631 )
2018
20
Anaphylatoxin C3a: A potential biomarker for esophageal cancer diagnosis. ( 29435296 )
2018
21
The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. ( 29946180 )
2018
22
The Role of PET-Based Radiomic Features in Predicting Local Control of Esophageal Cancer Treated with Concurrent Chemoradiotherapy. ( 29967326 )
2018
23
Correction to: Comprehensive Registry of Esophageal Cancer in Japan, 2011. ( 29948478 )
2018
24
The role of endosonography prior to endoscopic treatment of esophageal cancer. ( 29963792 )
2018
25
Early diagnostic potential of<i>APC</i>hypermethylation in esophageal cancer. ( 29440928 )
2018
26
Diagnosing conduit leak after esophagectomy for esophageal cancer by computed tomography leak protocol and standard esophagram: Is old school still the best? ( 29414520 )
2018
27
Intake of Dietary One-Carbon Metabolism-Related B Vitamins and the Risk of Esophageal Cancer: A Dose-Response Meta-Analysis. ( 29954131 )
2018
28
Comprehensive Registry of Esophageal Cancer in Japan, 2011. ( 29948477 )
2018
29
Near infrared fluorescent peptide nanoparticles for enhancing esophageal cancer therapeutic efficacy. ( 29973582 )
2018
30
The relationship between esophageal cancer, chagasic megaesophagus and HPV: myths, tales or reality? ( 29687834 )
2018
31
[The Efficacy of Definitive Chemoradiotherapy for Thoracic Esophageal Cancer on the Point of View Salvage Surgery]. ( 29362320 )
2018
32
<sup>18</sup> F-Fluorodeoxyglucose positron emission tomography can be used to determine the indication for endoscopic resection of superficial esophageal cancer. ( 29953743 )
2018
33
Future Perspectives of Surgery for Esophageal Cancer. ( 29962387 )
2018
34
Cervicothoracoscopic Approach for Esophageal Cancer in a Patient with Right-Sided Aortic Arch. ( 29411200 )
2018
35
Hot Tea and Esophageal Cancer. ( 29404600 )
2018
36
Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). ( 29948420 )
2018
37
The ability of silver(I) thiocyanate 4-methoxyphenyl phosphine to induce apoptotic cell death in esophageal cancer cells is correlated to mitochondrial perturbations. ( 29430579 )
2018
38
Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. ( 29433514 )
2018
39
SLC52A3 expression is activated by NF-I_B p65/Rel-B and serves as a prognostic biomarker in esophageal cancer. ( 29428966 )
2018
40
An explanatory and predictive model of the variation in esophageal cancer incidence on the basis of changes in the exposure to risk factors. ( 29324583 )
2018
41
Role of<i>MLH1</i>methylation in esophageal cancer carcinogenesis and its clinical significance. ( 29440913 )
2018
42
Role of ALDH1 in the prognosis of esophageal cancer and its relationship with tumor microenvironment. ( 28888039 )
2018
43
Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer. ( 29951984 )
2018
44
Thoracoscopic resection of esophageal cancer with a tracheal diverticulum. ( 29067556 )
2018
45
Salvage Surgery for Esophageal Cancer: How to Improve Outcomes? ( 29417405 )
2018
46
Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer. ( 29980971 )
2018
47
Neoadjuvant Treatments for Locally Advanced, Resectable Esophageal Cancer: A Network Meta-Analysis. ( 29441562 )
2018
48
Minimally invasive esophagectomy may contribute to long-term respiratory function after esophagectomy for esophageal cancer. ( 29444214 )
2018
49
Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer. ( 29963201 )
2018
50
Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial. ( 29306867 )
2018

Variations for Esophageal Cancer

UniProtKB/Swiss-Prot genetic disease variations for Esophageal Cancer:

75
# Symbol AA change Variation ID SNP ID
1 TGFBR2 p.Glu526Gln VAR_015816 rs121918714

ClinVar genetic disease variations for Esophageal Cancer:

6 (show top 50) (show all 486)
# Gene Variation Type Significance SNP ID Assembly Location
1 LZTS1 NM_021020.3(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh37 Chromosome 8, 20112608: 20112608
2 LZTS1 NM_021020.3(LZTS1): c.85T> C (p.Ser29Pro) single nucleotide variant Pathogenic rs28937897 GRCh38 Chromosome 8, 20255097: 20255097
3 LZTS1 NM_021020.3(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh37 Chromosome 8, 20111087: 20111087
4 LZTS1 NM_021020.3(LZTS1): c.355A> G (p.Lys119Glu) single nucleotide variant Pathogenic rs119473032 GRCh38 Chromosome 8, 20253576: 20253576
5 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh37 Chromosome 16, 78466465: 78466465
6 WWOX NM_016373.3(WWOX): c.872T> C (p.Leu291Pro) single nucleotide variant Pathogenic rs119487098 GRCh38 Chromosome 16, 78432568: 78432568
7 RNF6 NM_005977.3(RNF6): c.305G> A (p.Arg102Lys) single nucleotide variant Pathogenic rs121434522 GRCh37 Chromosome 13, 26789714: 26789714
8 RNF6 NM_005977.3(RNF6): c.305G> A (p.Arg102Lys) single nucleotide variant Pathogenic rs121434522 GRCh38 Chromosome 13, 26215577: 26215577
9 RNF6 NM_005977.3(RNF6): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121434523 GRCh37 Chromosome 13, 26789295: 26789295
10 RNF6 NM_005977.3(RNF6): c.724G> A (p.Ala242Thr) single nucleotide variant Pathogenic rs121434523 GRCh38 Chromosome 13, 26215158: 26215158
11 RNF6 NM_005977.3(RNF6): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic rs121434524 GRCh37 Chromosome 13, 26789288: 26789288
12 RNF6 NM_005977.3(RNF6): c.731G> A (p.Gly244Asp) single nucleotide variant Pathogenic rs121434524 GRCh38 Chromosome 13, 26215151: 26215151
13 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
14 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
15 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
16 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
17 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
18 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
19 TP53 NM_000546.5(TP53): c.524G> A (p.Arg175His) single nucleotide variant Pathogenic rs28934578 GRCh37 Chromosome 17, 7578406: 7578